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Objective: Long intergenic non-coding RNAs (lincRNAs) are emerging as key regulators in gene expres-
sion; however, little is known about the lincRNA expression changes that occur in osteoarthritis (OA).
Here we aimed to define a transcriptome of lncRNAs in OA cartilage, specifically comparing the lincRNA
transcriptome of knee and hip cartilage.
Method: RNA-seq was performed on nucleic acid extracted from hip cartilage from patients undergoing
joint replacement surgery because of either OA (n ¼ 10) or because of a neck of femur fracture (NOF;
n ¼ 6). After transcript alignment, counts were performed using Salmon and differential expression for
ENSEMBL lincRNAs determined using DESeq2. Hip RNA-seq lincRNA expression was compared to a knee
dataset (ArrayExpress; E-MTAB-4304). ChIP-seq data from ENCODE was used to determine whether
lincRNAs were associated with promoters (plncRNA) or unidirectional enhancer-like regulatory elements
(elncRNAs).
Results: Our analysis of the hip transcriptome identified 1692 expressed Transcripts Per Million (TPM 1)
Ensembl lincRNAs, of which 198 were significantly (FDR 0.05) differentially expressed in OA vs normal
(NOF) cartilage. Similar analysis of knee cartilage transcriptome identified 648 Emsembl lincRNAs with
93 significantly (FDR 0.05) differentially expressed in intact vs damaged cartilage. In total, 1834
lincRNAs were expressed in both hip and knee cartilage, with a highly significant correlation in
expression between the two cartilages.
Conclusion: This is the first study to use RNA-seq to map and compare the lincRNA transcriptomes of hip
and knee cartilage. We propose that lincRNAs expressed selectively in cartilage, or showing differential
expression in OA, will play a role in cartilage homoeostasis.
© 2019 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is a common debilitating musculoskeletal
disease that affects the articulating joints and for which there re-
mains no cure. The burden of OA continues to increase worldwide.
In the United Kingdom, 89,288 hip and 98,591 knee primaryD.A. Young, Institute of Ge-
y, Newcastle upon Tyne, NE1
titute of Genetic Medicine,
on Tyne, NE1 3BZ, UK.
r Ltd on behalf of Osteoarthritis Re
l., Identification of long non
10.1016/j.joca.2018.12.015replacements were recorded in the National Joint Registry in 2015,
with the vast majority attributable to OA1. Clinically OA is charac-
terised by pain, stiffness and deformity of the affected joint with
loss of function. Macroscopically there is degradation and loss of
articular cartilage with subsequent sclerosis of the underlying
bone. At the molecular level, changes to chondrocytes and the
composition of the extracellular matrix have been extensively
investigated, with a maladaptive milieu of growth factors, inflam-
matory cytokines (e.g., Tumour Necrosis Factor a; TNFa) and
degradative enzymes such as matrix metalloproteinases (MMPs)
contributing to cartilage destruction2.
Gene expression changes in OA cartilage have been well
characterised and indicate alterations in chondrocytesearch Society International. This is an open access article under the CC BY license
-coding RNAs expressed in knee and hip osteoarthritic cartilage,
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx2homoeostasis and activation in response to this maladaptive
milieu3,4. Long non-coding RNAs (lncRNAs) are emerging as key
regulators of gene expression. They are conventionally defined as
being over 200 nucleotides in length with many hallmarks of
mRNA transcripts but an absence of coding ability. Many appear
well conserved5,6 though there is also evidence to the contrary6,7
and they have been demonstrated to have tissue specificity,
perhaps more so than protein-coding transcripts8,9. Their mech-
anisms of action, although not fully characterised, are increasingly
being recognised. Theymay act in cis or trans at the transcriptional
and post-transcriptional level as guides or scaffolds for DNA, RNA
and protein binding10,11, manifesting e for example e in chro-
matin remodelling12. LncRNAs have key roles in development and
many are proposed to have impact on disease, for example, the
lncRNA HOTAIR is dysregulated in several cancers, and its over-
expression has been shown to drive breast cancer metastasis13.
Nevertheless, potential key regulatory roles for lncRNAs in both
health and disease remain underexplored.
We have previously identified lncRNAs in human articular
cartilage but little is known about the changes in lncRNA expres-
sion that occur in OA14. One recent study used RNA sequencing
(RNA-seq) to look at IL-1b-induced lncRNAs in cultured chon-
drocytes isolated from human hip OA cartilage15. Other studies
have used microarrays for transcriptome profiling of lncRNAs in
knee OA cartilage3,4,16, and upon stimulation of isolated chon-
drocytes with key pro-inflammatory mediators IL-1b4,15 and TNFa4,
but such studies are limited by pre-existing probe design.
Whilst independent epidemiological risk factors have been
established for both hip and knee OA, few studies have compared
gene expression between the two.We have previously explored the
gene expression profile of hip OA cartilage in comparison to age-
matched neck of femur (NOF) fracture cartilage (NOF)17. Interest-
ingly, when comparing our dataset to data from a similar study of
knee OA cartilage we found only a small subset of differentially
expressed genes in common but a large overlap in dysregulated
canonical pathways. Other knee and hip OA comparison have
included differential DNA methylation analysis of articular carti-
lage18,19, identifying a large number of differentiallymethylated loci
between both the joint site and disease-status.
Here we identify a repertoire of long intergenic non-coding
RNAs (lincRNAs) in both hip and knee articular cartilage and the
expression changes in OA progression. We highlight differential
expression of lincRNAs between knee and hip to explore any
pathological differences between the two at the molecular level.
Methods
Cartilage samples
Human hip articular cartilage samples were obtained from
consented patients undergoing joint replacement surgery due to
either end-stage OA or intracapsular NOF fracture with Ethical
Committee approval from the Newcastle and North Tyneside
Health Authority. Joints were inspected macroscopically and
scored using a scheme adapted from Noyes classification20 to
include the presence of osteophytes [Fig. 1(A) and (B)]. Samples
used in this study included those previously scored and re-
ported17. In addition, radiological grading of the pre-operative X-
rays was carried out by two blinded orthopaedic trainees. The
Kellgren and Lawrence grading systemwas used to score the latest
pre-operative hip X-ray for the OA group. NOF hips were scored
using the trauma admission X-rays. The Kellgren and Lawrence
grading system is a five-tiered system (0- no arthritis to 5- severe
arthritis) that takes into account joint space narrowing, osteo-
phytes, sclerosis, presence of cysts and bone deformity. ThePlease cite this article as: Ajekigbe B et al., Identification of long non
Osteoarthritis and Cartilage, https://doi.org/10.1016/j.joca.2018.12.015grading system has been validated for different joints with good
inter-observer reliability21,22. Further to the overall grade, the
observers assigned a binary scoring system for the presence of
each specific feature of the grading system. Data was also
collected from the contralateral side in order to avoid the poten-
tial confounding factor of displacement due to the fractured NOF
[Fig. 1(C)]. For all joints, macroscopically normal cartilage was
collected, snap frozen in liquid nitrogen within 2 h of surgery and
stored at 80C prior to RNA extraction.
For knee, we used a pre-existing RNA-seq dataset from eight
patients undergoing total knee arthroplasty for OA (age range
65e79 years, mean age 70.3; Supplementary Fig. 1(B)). The carti-
lage samples were from paired osteochondral specimens isolated
from the ‘intact’ posterior lateral condyle (PLC) and the ‘damaged’
distal medial condyle (DMC) - sites OA23 (Supplementary Fig. 1(C)).
To characterise the cartilage tissue, the PLC and DMC samples were
graded histologically using a modified Mankin score24, which
confirmed the DMC cartilage was significantly more damaged than
that from the PLC (Supplementary Fig. 1(C) and (D)).
RNA extraction and sequencing
For the hip RNA-seq, total RNAwas isolated directly from female
articular cartilage samples (OA, n ¼ 10; NOF, n ¼ 6) as described25
and RNA integrity verified as previously described17. mRNA was
purified and 78-base paired-end sequencing performed on an
Illumina Genome Analyzer IIx (Illumina Inc., Saffron Walden, UK).
Sequencing reads quality controls were as described26. Fastq files
are available to download from the National Center for Biotech-
nology Information Expression Omnibus GSE111358. On average
each sample contained >22 million mapped read counts (see
below), which is sufficient, given the number of replicates to detect
differentially expressed genes with an False Discovery Rate (FDR)
<0.05 with a power close to 127. Knee RNA-seq data was from Dunn
et al.23 ArrayExpress (E-MTAB-4304). As with the hip RNA, total
knee RNAwas extracted from liquid nitrogen frozen cartilage using
TRIzol (LifeTechnologies) and homogenisation followed by a final
purification using Qiagen RNeasy columns (Qiagen). Following
sequencing on an Illumina HiSeq 2000 approximately 39 million
reads per sample were generated23.
RNA-seq analysis
For both knee and hip datasets, transcript counts were esti-
mated using Salmon (version 0.7.2) in quasi-mapping mode against
human reference genome hg38 (release 87) with default settings.
Salmon estimated counts were summarized to gene level using the
tximport package in RStudio for usewith DESeq2. The RUVg in silico
approach was used to remove unwanted technical variation. RUVg
variation factors were added into the design model of DESeq2 for
differential expression testing. Differential expression analysis was
performed paired and unpaired for OA knee and hip, respectively.
All genes were included in DESeq2 analysis before filtering for
genes designated as a “lincRNA” biotype by ENSEMBL. Heatmaps
were generated with log2 transformed and normalised counts us-
ing the pheatmap() function in RStudio.
To generate scatterplots, the removeBatchEffect() function from
limmawas used with the DESeq2 normalised and log2 transformed
counts, giving the RUVg unwanted variation factors as a co-variate.
The ggplot2 package was used in Rstudio to build the scatterplots.
To generate genome browser tracks, reads were aligned to hg38
using the HISAT2 aligner. Alignment files were converted into
bigwig format first by converting into bedgraph format using
BEDTools genomecov and then the bedGraphToBigWig utility from
UCSC.-coding RNAs expressed in knee and hip osteoarthritic cartilage,
Fig. 1. Differential lincRNA expression in NOF compared to OA hip cartilage. A. A NOF and OA femoral head used in this study. The OA femoral heads typically showed exposed bone
and fibro-cartilage. B. Blinded cartilage macroscopic scores based on the Noyes classification20. Line mean, error bars are maximum and minimum, **represents P < 0.01. C. Hip
osteoarthritis for NOF and OA patients were calculated from X-rays (as described in Methods) to give an overall grade (0e5) based on the Kellgren and Lawrence. Statistical
significance was determined using a Mann Whitney U test where * P < 0.05. D. Scatter plot of lincRNA counts in OA vs NOF RNA-seq. Significant lincRNAs (DESeq2, FDR < 0.05) are
coloured in red, the shading represents a log2 fold change of 2 from the regression line. A Spearman's rank test was used to assess the correlation between samples. E. Heatmap of
top 25 differentially expressed lncRNAs in hip OA (peach) vs NOF (cyan). F. Principal component plot, hip OA vs NOF RNA-seq samples (autosomal lincRNAs only).
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx 3Enhancer and promoter lincRNA derivation
Histone ChIP-seq read alignment tracks for H3K4me3,
H3K4me1 and H3K27ac for Roadmap cell type E049 (bonemarrow-
derived chondrocytes) accessed fromNCBI GEO database, accession
GSE19465. Bed tracks were converted to hg38 using the UCSC
liftover tool and converted to bam format using the bedtobamPlease cite this article as: Ajekigbe B et al., Identification of long non
Osteoarthritis and Cartilage, https://doi.org/10.1016/j.joca.2018.12.015utility in bedtools. Sorted bam files were used as input into
ngs.plot.r28 to plot read coverage around the transcription start
sites (TSS) of lincRNAs (±2000 bp). LincRNAs with a mean Tran-
scripts Per Million (TPM) > 1 in all hip and knee samples were
included. H3K4me1 and H3K4me3 coverages were plotted as bam
pairs. The gene order was extracted using R from H3K4me1/
H3K4me3 heatmaps and used to plot H3K27ac read coverage.-coding RNAs expressed in knee and hip osteoarthritic cartilage,
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx4Results
For hip, we performed RNA-seq on cartilage RNA extracted from
OA and NOF patients undergoing total hip arthroplasty. The NOF
samples had a significantly lower level of OA than the OA samples,
both macroscopically17 and by X-ray analysis [Fig. 1(A)e(C)]. There
was no significant difference in the ages of the consented patients
in each grouping (Supplementary Fig. 1(A)). RNA-seq analysis of all
hip cartilage samples identified 1692 Ensembl lincRNAs with an
average TPM 1. Ensembl lincRNA classification is based on cDNA
alignments overlapping chromatin methylation regions (H3K4me3
or H3K36me3) outside of protein-coding loci. LincRNAs (long
intergenic noncoding RNAs) are better described as long inter-
vening non-coding RNAs and analysis of the this portion of lncRNAs
avoids the complication arising from overlap with coding genes7.
When stratifying these hip cartilage samples into OA and NOF,
DESeq2 analysis identified 198 lincRNAs as differentially expressed
(FDR 0.05) with 28 of these showing a fold change 2 (log2 fold
1) (Fig. 1(D) and (E); Supplementary Table 1). Of these 198 and 28,
89 and 7 were increased, respectively, in OA hip cartilage compared
to NOF. Importantly, when using just the expression data from
these 1692 lincRNAs principal component analysis (PCA) segre-
gated the OA and NOF samples, suggesting lincRNA expression
alone is enough to define disease severity [Fig. 1(F)]. The most
upregulated lincRNAs in hip OA included PART1, LINC01139 and
NORAD, while the most downregulated included LUCAT1, MEG3
and LINC01679. LincRNAs have been proposed to regulate local
gene expression29 but we could find no correlation between OA
severity-associated changes in lincRNA expression with those of
the neighbouring protein-coding genes (data not shown).
Next we performed a similar RNA-seq analysis pipeline for a
previously published knee OA RNA-seq dataset23. Cartilage for the
knee study was taken from eight patients and contained paired
osteochondral samples isolated from both the intact PLC and theFig. 2. Differential lincRNA expression in paired OA-intact (PLC) compared to OA-damaged D
seq. Significant lincRNAs (DESeq2, FDR < 0.05) are coloured in red, the shading represents a l
the correlation between samples. B. Heatmap of top 25 differentially expressed lncRNAs in d
(1e8).
Please cite this article as: Ajekigbe B et al., Identification of long non
Osteoarthritis and Cartilage, https://doi.org/10.1016/j.joca.2018.12.015damaged DMC for each donor (Supplementary Fig. 1(C) and (D)).
This analysis identified a total of 648 Ensembl lincRNAs with a TPM
1 in all damaged DMC and intact PLC OA knee cartilage samples.
In the knee data, 93 lincRNAs were differentially expressed (FDR
0.05) between the damaged (DMC) and intact (PLC) cartilage
groups with 13 of these showing a fold change 2 (log2 fold 1)
(Fig. 2(A) and (B); Supplementary Table 2). Similarly, of these 93
and 13, 20 and 8 respectively were upregulated in the damaged
knee cartilage, the remainder downregulated. The most upregu-
lated lincRNAs in damaged knee cartilage were CRNDE, MIR22HG
and LINC01614. The most downregulated lincRNAs included MEG3,
ILF3-AS1 and LINC01089.
When comparing lincRNAs between hip and knee 572 were
detected in common between the cartilages from both joints
[Fig. 3(A)]. Furthermore, the average expression level of all lincR-
NAs between the two cartilages showed a good degree of correla-
tion [Fig. 3(B)], especially when considering the known variability
of lincRNA expression levels between tissues7. Of the differentially
expressed lincRNAs from hip or knee only 20 lincRNAs were in
common including established lincRNAs such as NEAT1 and MEG3
(Table I). However, when using the whole lincRNA dataset for each
joint ranked by degree of differential expression using the
Rankerank Hypergeometric Overlap (RRHO) threshold-free algo-
rithm30 a robust correlationwas observed in lincRNAswith reduced
expression in intact knee and NOF cartilage [Fig. 3(C)]. Of course,
one important caveat is that neither dataset contains a true non-OA
control.
Further to identifying the lincRNAs altered during OA progres-
sion and cartilage damage we also sought to determine whether
any lincRNAs exhibit joint site selective expression levels. Initially
we examined the relative expression of all coding transcripts (after
removing the mitochondrial encoded genes) between the differing
cartilage joint sites. Correlation analysis of the expression level of
all coding mRNAs gave a Spearman's Rank of 0.87 (P < 0.00001)MC) knee cartilage. A. Scatter plot of lincRNA counts in OA knee intact vs damaged RNA-
og2 fold change of 2 from the regression line. A Spearmans rank test was used to assess
amaged (pink) vs intact (cyan) knee OA RNA-seq samples. Patient pairings are indicated
-coding RNAs expressed in knee and hip osteoarthritic cartilage,
Fig. 3. Joint site comparisons in lincRNA expression. A. Venn diagrams showing the 572 lincRNAs in common between hip and knee and those differentially expressed between the
tissues and disease status at both joint sites (20). B. Scatter plot of mean lincRNA counts (TPM) for all hip samples (NOF and OA hip) vs all knee (intact and damaged) samples. C.
Rankerank hypergeometric overlap representation of lincRNA lists ranked by the degree of differential expression observed in the two profiling experiments (positive values
indicate an enrichment of overlapping lincRNAs). Key depicts elog10 P value. Axis graphs depict ranked gene regulation with red and blue highlighting upregulated and down-
regulated lincRNAs, respectively, in damaged knee or OA hip datasets. D. Total read coverages of each sample group on UCSC Browser hg38. PART1 expression in damaged & intact
knee OA, and hip OA & NOF. E. Read coverage plot on UCSC Browser hg38. MEG3 expression in damaged & intact knee OA, and hip OA & NOF. F. MEG3 expression in individual NOF
vs hip OA and intact vs damaged paired knee OA samples. TPM for each experimental dataset are presented.
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Table I
Differentially expressed LincRNAs in common between OA hip vs NOF and intact vs damage knee cartilage
Ensembl ID lincRNA name Hip_Av_TPM Knee_Av TPM Hip log2 Fold Change Knee log2 Fold Change Hip adjusted pvalue Knee adjusted pvalue
ENSG00000260807 RP11-161M6.2 73.26 21.41 0.669 0.692 3.17E-04 3.05E-06
ENSG00000230724 LINC01001 40.41 4.61 0.735 0.659 4.91E-04 6.60E-03
ENSG00000214548 MEG3 381.13 30.04 0.864 1.350 1.25E-03 4.23E-11
ENSG00000261200 RP11-989E6.10 5.91 0.55 0.629 0.719 1.43E-03 1.25E-02
ENSG00000235815 RP1-125N5.2 8.95 9.94 1.220 0.684 1.56E-03 3.14E-03
ENSG00000230606 AC159540.1 32.76 14.93 0.504 0.646 1.72E-03 5.21E-03
ENSG00000179523 EIF3J-AS1 21.25 17.74 0.405 0.322 2.01E-03 6.31E-03
ENSG00000212694 LINC01089 20.08 14.49 0.421 0.792 2.21E-03 3.01E-06
ENSG00000272374 RP3-329A5.8 0.61 0.23 0.746 0.849 3.07E-03 1.29E-02
ENSG00000203709 C1orf132 8.65 0.65 1.058 0.462 3.28E-03 1.88E-02
ENSG00000224652 LINC00885 0.99 0.94 0.887 0.713 5.05E-03 8.52E-03
ENSG00000230487 PSMG3-AS1 4.77 2.51 0.625 0.504 7.08E-03 7.18E-03
ENSG00000245532 NEAT1 1149.80 250.31 0.865 0.407 9.60E-03 4.22E-02
ENSG00000255135 RP11-111M22.3 11.10 12.76 0.389 0.390 1.20E-02 4.41E-02
ENSG00000232931 LINC00342 6.02 2.93 0.284 0.566 2.93E-02 2.41E-02
ENSG00000283445 RP11-63G10.4 1.90 0.79 0.406 0.758 2.99E-02 2.84E-03
ENSG00000261888 AC144831.1 1.34 1.14 0.599 0.727 3.00E-02 2.63E-03
ENSG00000255284 AP006621.5 4.79 4.29 0.451 0.531 3.39E-02 4.87E-02
ENSG00000265485 RP11-449D8.1 2.07 4.83 0.638 0.419 4.93E-02 3.64E-02
ENSG00000256321 RP11-153K16.1 3.02 2.05 0.496 0.794 4.99E-02 3.83E-03
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx6(Supplementary Fig. 1). 18 of the 25 most abundant mRNAs were
common between the two joint sites, with the remainder found in
the top 100 expressed transcripts, the only exception being su-
peroxide dismutase 3 (SOD3) which was expressed higher in hip.
Patterning differences between the two joint sites were reflected by
differential expression of HOX genes with more 30 HOX cluster
genes (HOXA4-6 and HOXB1-3) showing higher expression in hip,
with more 50 genes (HOXD8-10) enriched in knee e possibly
demonstrating maintenance of the temporal sequential expression
pattern observed during development31. Correlation analysis of the
expression level of all the lincRNAs gave a Spearman's Rank of 0.51
(P < 0.00001) [Fig. 3(B)]. Of the 10 most abundant lincRNAs in each
cartilage type, 8 were in common, with the remainder being found
in the top 100 expressed lincRNAs. Some lincRNA showed joint site
differential expression. For example, in knee cartilage the lincRNA
PART1 was more abundant than in hip, yet was only significantly
upregulated in OA hip cartilage vs NOF [Fig. 3(D)]. On the contrary
MEG3 was more abundant in hip compared to knee cartilage
[Fig. 3(E)] but differentially expressed in both [Fig. 3(E) and (F)].
Numerous studies have identified a large number of lincRNAs,
far outstripping the number of coding transcripts. However, the
bottleneck in research has been in determining which lincRNAs
are functional. Several studies have attempted to address how to
identify functional lincRNAs. We used a modification of the
method defined by Marques et al.32 which divides lincRNAs as
either promotereassociated lncRNAs (plncRNA) or unidirectional
enhancer-like regulatory element associated lncRNAs (elncRNAs)
based on their overlying chromatin status. plncRNAs and elncR-
NAs are defined as those with an enriched H3K4me1 or H3K4me3
mark respectively at or around their TSS. We used histone ChIP-
seq data from bone marrow derived chondrocytes generated as
part of Roadmap33 to define the H3K4Me1 to H3K4Me3 ratio
around (þ/ 2 kbp) the TSS of the lincRNAs expressed in both hip
and knee cartilage (Fig. 4). We also included H3K27Ac as a
marker of biological activity. Approximately 75% of these carti-
lage lincRNAs were defined as plncRNAs; those which have been
proposed have a function beyond regulation of the nearest
gene32. plncRNAs had a slightly higher, but non-significant,
expression levels compared to elncRNAs (plncRNA mean TPM of
6.82 and 6.35 for hip and knee respectively vs an elncRNA mean
TPM of 4.37 for hip and knee respectively). plncRNAs included
PART1 and MEG3.Please cite this article as: Ajekigbe B et al., Identification of long non
Osteoarthritis and Cartilage, https://doi.org/10.1016/j.joca.2018.12.015Discussion
Current non-coding RNA research in OA has generally focused
onmicroRNAs. Here for the first timewe have used RNA sequencing
to define lincRNA expression in OA in both hip and knee cartilage.
We identified 198 lincRNAs altered in hip OA progression and 93 in
damaged knee cartilage of which 20 were in common. We addi-
tionally identified lincRNAs with joint site selectivity and further
assessed their potential functionality by interrogating their chro-
matin status. Pearson et al., have also used RNA-Seq to profile
lncRNAs in chondrocytes, although their focus was on those
lncRNAs upregulated by IL-115. In contrast to our RNA extracted
from cartilage, their study makes use of isolated chondrocytes. It is
known that chondrocytes that are isolated dedifferentiate, adopt-
ing a more fibroblastic phenotype34e36. The authors also derived
some of their non-OA cartilage from post-mortem donors, but only
for real-time PCR analysis of a subset of IL-1-induced lncRNAs.
Conversely the hip and knee OA samples used for RNA-seq in our
study were obtained from live tissue donors and processed within
2 h post-surgery.
Interestingly, lincRNAs can be detected within exosomes pre-
sent in extra-cellular fluid such as serum and therefore could
represent biomarkers of disease status, as suggested for cancer37.
Recently for OA, exosomal levels of lncRNA PCGEM1 in synovial
fluid has been proposed as a biomarker for different stages of
disease38.
Importantly, we have highlighted lincRNAs that are differen-
tially expressed in damaged OA cartilage. Of interest, we observed
that the lincRNA ROCR (ENSG00000228639), which we identified
and characterised as a critical regulator of MSC chondrogenesis, is
significantly down-regulated in damaged knee cartilage, but not
differentially expressed in the hip dataset14,39. Further, our results
show that MEG3 is significantly downregulated in both OA hip and
damaged knee OA cartilage, confirming knee cartilage data from Su
et al.40 and data from a rodent OA-model41. However, this some-
what contrasts with the findings of Fu and colleagues where MEG3
transcript isoforms were both down or upregulated in knee OA
cartilage compared to age-matched non-OA controls3. MEG3 has
been principally identified as an influential tumour suppressor,
whereby it negatively regulates cell proliferation and induces
apoptosis42e45. Downregulation of this imprinted lincRNA has been
associated with multiple cancers43e47. In a rat OA model MEG3 has-coding RNAs expressed in knee and hip osteoarthritic cartilage,
Fig. 4. Histone ChIP-seq analysis of chondrocyte lincRNA. Histone ChIP-seq read alignment tracks for H3K4me3, H3K4me1 and H3K27ac were analysed from Roadmap cell type
E049 (bone marrow-derived chondrocytes). Data presented are from the 1558 lincRNAs with a mean TPM > 1 in all hip and knee samples. Read coverage density is plotted around
the TSS of lincRNAs (±2000 bp). H3K4me1 and H3K4me3 coverages were plotted as bam pairs using ngs.plot, with the same lincRNA order used to subsequently plot the H3K27ac
read coverage. To define enhancer-associated (elncRNA) and promoter-associated (plncRNA) lincRNAs a threshold of 0.5 of H3K4me1/H3K4me3 was defined (red line).
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx 7been proposed to regulate miR-16 expression, thus indirectly
regulating Smad741. Indeed, others have shown that MEG3 may
negatively regulate the Transforming growth factor (TGF)b signal-
ling pathway48, with isolated fibroblasts overexpressing MEG3
unable to proliferate when incubated with TGFb49. TGFb plays a
somewhat pleiotropic role in both normal and OA joints. In normal
tissue it is active only transiently following joint loading while in
OA joints high TGFb activity is detected50. MEG3 may additionally
have a role in the osteogenic differentiation of MSCs. Zhuang et al.,
examined MEG3 and BMP4 expression in isolated MSCs. In these
cells the overexpression of MEG3 resulted in greater expression of
osteogenic markers such as RUNX2, whilst reducing MEG3
expression had the opposite effect51.
We have also highlighted lincRNAs that may be selective for
knee (e.g., PART1) and hip (e.g., MEG3), respectively. Interestingly,
thoughmany lincRNAs were shared between the two joints only 20
lincRNAs were differentially expressed in common between the
disease states of both joint sites. When we previously used
microarray analysis to explore gene expression changes in normal
and OA cartilage of hip and knee, we similarly found a limited
overlap (approximately 10%) of differentially expressed genes17. The
two joints in question do have independent risk factors for OA such
as gender, ethnicity and occupation52e54, the molecular and path-
ophysiological basis of which remain elusive. Further, although
highly correlative, the two joint sites do have characteristic gene
expression programmes, potentially regulated by differential HoxPlease cite this article as: Ajekigbe B et al., Identification of long non
Osteoarthritis and Cartilage, https://doi.org/10.1016/j.joca.2018.12.015gene expression31. Interestingly, the Hox gene cluster is well known
to include a number of well-studied non-coding transcripts55. Of
particular interest, lncRNA-HIT appears a critical regulator of early
limb development56.
The challenge remains to determine which of the lincRNAs we
and others have identified are functional and which lack a specific
biological function. Although lincRNA loci may contain active pro-
moters and associated chromatin marks and the transcripts
themselves can be capped, spliced and polyadenylated, none of
these features offer an informative indicator of function. Marques
et al., describe a multifaceted approach to discerning the biological
relevance of lincRNAs32. Using their criteria, we classified the
cartilage expressed lincRNAs into plncRNAs and elncRNAs, with the
majority in our analysis being plncRNAs. The association of
plncRNAs with their own promoter suggests a potentially more
evolutionary conserved role than their elncRNA counterparts.
Testing the function of lincRNAs still remains a challenge. Gene
function is often initially sought using experimental animals, most
commonly the genetically tractable mouse. However, determining
the function of a lncRNA by its deletion in mice can also be fraught
since removing the genetic loci can also disrupt important under-
lying DNA elements such as enhancers57. Moreover, using
comparative genomics to understand the function of lincRNAs is
not straightforward since the majority show little sequence or
splicing pattern conservation. There are notable exceptions, but
these tend to be those lncRNAs that are relatively highly-coding RNAs expressed in knee and hip osteoarthritic cartilage,
B. Ajekigbe et al. / Osteoarthritis and Cartilage xxx (xxxx) xxx8expressed58. With these caveats in mind, much recent work has
described interactions between short and lncRNAs59. In OA, several
lncRNAs have been shown act as potential ‘sponges’ to regulate
microRNA function60,61.
In summary, we have outlined lincRNA expression patterns in
both hip and knee OA cartilage. We have highlighted differential
expression between hip OA and NOF and between intact and
damaged knee OA (sites of low and high mechanical loading,
respectively). We have additionally highlighted significantly
changing lincRNAs that are common to both, namely the tumour
suppressor MEG3, which is downregulated. Mondal et al. identified
MEG3 as forming DNA-RNA triplex complexes with chromatin,
targeting constituents of the TGFb signalling pathway; indeed48,
fully characterising themechanisms of action of lincRNAs in general
remains another key area for development.
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